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MM.CBA myeloid leukemia cell line did not block an effective 
GVL response, despite reducing lethal GVHD. These results 
demonstrate hat donor CD4+CD25 + T ceils infused early post- 
transplant can control the full development of GVItD without 
sacrificing asufficient GVL effect. 
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CD25 EXPRESSION DISTINGUISHES FUNCTIONALLY DISTINCT 
ALLOREACTIVE CD4+CDI34+ T CELL SUBSETS IN ACUTE GVHD 
Mazia'r.~, R.T.; Zhm~g, X.; Streete*', P.R. Medicine, OHSU, Port- 
land, OR. 
CD134 fOX40) is expressed on activated CD4+ donor T cells in 
antinals with aGVHD. Using a P--> FI rat BMT model of 
aGVHD, activated CD4+134+ T cells are shown to have a central 
role. These cells were evaluated, in vivo, using adoptive transfer. 
GVHD-associated donor CD4+134+ T cells were isolated from 
animals on D10, and the isolated cells were transferred to irradiat- 
ed (600R) F1 recipients with normal donor CD4-depleted CD8+ 
lymph node cells. This cell combination yielded lethal aGVHD in 
transplant recipients, while irradiated (600R) F1 control animals 
receiving either population alone failed to develop disease. Thus, 
aGVHD-associated CD4+134+ cells, as the only source of donor- 
derived CD4+ T cells, promote disease after adoptive transfer. 
However, in vitro challenge of the the aGVHD-associated 
CD4+134+ T cells with either host alloantigen or ConA provided 
only minimal proliferation. This T cell population was able to be 
stratified into CD25- and CD25+ subsets. CD4+134+25- T cells 
were selectively found in organized lymphoid tissues while 
CD4+134+25+ T cells were located in both organized lymphoid 
tissues and inflamed extralymphoid tissues. Although both 
CD4+134+ T cell subsets were observed throughout the disease 
course (D4 -->end stage), the CD4+134+25+ T subset predomi- 
nated on day 4. On D10, CD4+134+25- T cells proliferated to 
both ConA and allogeneic host leukocytes, while CD4+ 134+25 + T 
cells exhibited an anergic profile, with minimal response to either 
stimulus. Short-term culture of the CD4+134+25+ T cells to IL-2 
overcame T cell anergy, and cells recovered were alloresponsive. 
Thus, both CD4+ 134+ T cell subsets are comprised of alloreactive 
cells. When the anergic CD4+134+25+ T cells were added to 
responsive CD4+134+25- T cells, the CD4+134+25- cells no 
longer responded to antigen, indicating that CD4+134+25+ T 
cells inhibited the CD4+134+25- cell subset. The distinct issue 
localization, temporal induction and functional properties of these 
CD4+134+25- and CD4+134+25+ alloreactive T cell subsets ug- 
gest an unanticipated degree of complexity in the CD4+ T cell 
compartment in aGVHD. Clarification of the physiologic roles of 
the CD4+CD134+ subpopulations will provide insights into the 
temporal evolution of aGVHD. 
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T-CELL APOPTOSIS FOLLOWING NON-MYELOABLATIVE HEMATOPOI- 
ETIC CELL TRANSPLANTATION (HCT) 
Bhiis,~a~, FU; Si~lgleton, K.LS; LiTl, M.e; TabelliM, L.I; Fra~Tgoul, 
H.S; Damodaran, A.I; Hansen, ff.A. I i. Fred HlttchinsoJ~ Cai~cer 
Research Cellter, Seattle, WA; 2. National Taiwc.m UT~iversity, 
Taipei, TaiwaT~; 3. Vanderbih Unive~'sit~ Medical Ce~ter, 
Nashville, TN. 
We have previously demonstrated that PBMC from patients 
with aGVHD have high spontaneous'apoptosis following mye- 
loablative HCT. Short-term culture in the presence of dexam- 
ethasone or anti-CD3 monoclonfll antibody (Hum291) induces 
further apoptosis. We recently reported that monitoring sponta- 
neous; dexamethasone and anti-CD3 induced apoptosis may be 
useful for predicting steroid treatment outcome of GVHD in 
myeloablative HCT. We classified the outcome of steroid therapy 
into: (i)CR:complete response (no recurrence following steroid 
withdrawal) (ii)PR:partial/intermediate response(limited cGVHD, 
successfully withdrawn from immunosuppression) a d (iii) steroid 
dependent/refractory(SD/R): refractory GVHD or extensive 
GVHD requiring prolonged steroid/salvage therapy. Steroid 
dependent/refractory GVHD patients were very sensitive to anti- 
CD3 induced apoptosis after 4-weeks of steroid therapy. We now 
report our results in 25 patients undergoing non-myeloablative 
transplants. PBMC were obtained between day18-35 post-trans- 
plant and cultured for 24hours in medium and with Hum291 
(0.Sgg/ml). Apoptosis was measured by staining with 7AAD. In 
matched sibling donor transplants spontaneous apoptosis at day 
19-25 was 19.8+/-7.6% in 6 patients with aGVHD and 7.5+/- 
3.4% in 4 patients without any aGVHD(p<0.05) developing with- 
in 4 weeks of the assay. Spontaneous apoptosis was higher in URD 
transplants: 40.2+/-25.4% in 5 patients without aGVHD and 
I4.8+/-11.4% in 5 patients with aGVHD. GVHD requiring 
steroid therapy developed in 20 patients (10/14MSD, 10/11URD) 
between day 6-83 post-transplant (median 37.5 days). Assays were 
repeated after 4 weeks of steroid therapy. There was preferential 
anti-CD3 induced apoptosis in the SD/SR group(see table below). 
The pattern of apoptosis here is different from myeloablative 
transplantation, with an unexplained high spontaneous apoptosis 
in URD transplants without aGVHD. Preferential anti-CD3 
fuduced apoptosis occurs in non-myeloablative transplant patients 
who subsequently develop SD/SR GVHD. The correlation how- 
ever is not as strong, possibly due to other confounding factors 
including changing immune suppression i the non-myeloablative 
setting. 
Response Spontaneous Anti~CD3 p-value 
CR(n=4) 20.5+/7.9 23.4+/-8.1 NS 
PR(n=4) 11.7+/ 11.0 13.6+/-12.9 NS 
SD/SR(n=I2) 9.98+/-9.94 28.99+/9.9 ] <0.05 
I 
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THE LEUKEMIA-ASSOCIATED ANTIGEN PRI IS DERIVED FROM BOTH 
PROTEINASE 3 AND NEUTROPHIL ELASTASE PROTEINS 
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Marrow TraTz~Flantatio~, M. D. AJldersoTl Cancer Centre1", Hous- 
toTz, TX. 
PRI is an HLA-A2-restricted peptide leukemia-associated 
antigen that is contained within proteinase 3 (P3). We have 
shown that killing of leukemia cells by PRl-specific CTL corre- 
lates with P3 overexpression. However, the PR1 sequence is 
also contained within neutrophil elastase (NE), which is also 
aberrantly expressed in leukemia cells. To determine whether 
PR1 is processed and presented ffmn either protein, we used 
P3- and NE-transfected B cells as target cells in a proliferation 
assay with PRl-specific T cells. Full-length P3 and NE cDNA 
was cloned from the promyclocytic HL-60 cell line based on 
published sequences. The sequences were subcloned into an 
EGFP-containing vector (pCMS-EGFP) with a CMV promoter 
to drive constitutive xpression. The B cell line, HMy-CIR, 
previously stably transfected with the HLA-A*0201 gone, was 
transfected with P3-pCMS-EGFP and NE-pCMS-EGFP by 
electroporation for 24 hours. GFP expressing cells (P3- 
HMy.CIR-A2 and NE-HMy.CIR-A2, respectively) were select- 
ed by FACSorting and high transfection levels were confirmed 
by fluorescence microscopy. Quantitative real time PCR 
showed mRNA transcripts from one of two selected P3-trans- 
fected clones were only 2.6-fold less than HL-60 cells (p = 
0.07), and only 1.5-fold less in a second clone (p = 0.3). By con- 
trast, NE transcript numbers from a transfected clone were 7- 
fold.less than in HL-60 cells. Western blotting confirmed pro- 
tein expression in the NE-HMy.CIR-A2-transfected cells, 
although expression was similarly less than in HL-60 cells. 
PRl-specif ic CTL lines elicited from two healthy donors 
showed stimulation i dices (SI) of 1.3 and 2.4 When coincubated 
with P3-HMy.CIR-A2 target cells during BrDU incorporation, 
confirming that PR1-CTL recognize PR1 peptide processed 
and presented from P3. Interestingly, PR1-CTL also recog- 
nized NE-transfected cells, with SI of 1.5 and 2.1. No recogni- 
tion of non-transfectants or parent HMy.CIR (A2-) was 
observed. These results demonstrate that, in addition to P3, 
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